Share
communityprotocolsnutrition

Both Parents Died of Alzheimer's. How One APOE4 Carrier Rebuilt His Life. | Phoenix Member Stories

His p-tau came back at 0.09. But that's not even the best part of his story.

12 min read

Key Takeaway

Phoenix member John Yoder, APOE 3/4 with both parents lost to Alzheimer's, discovered three critical insights after starting his protocol: taking diphenhydramine (Benadryl) nightly for 20+ years suppresses deep sleep and has been linked to increased dementia risk in long-term users, APOE4 carriers process alcohol very differently than non-carriers (Oura HRV crashes after 1-2 drinks), and his p-tau result of 0.09 (well below the 0.18 concern threshold) gave him measurable evidence that stopping wrong interventions is often the highest-impact change.

Definition

The cumulative effect of medications that block acetylcholine, associated with increased dementia risk in long-term users.

Anticholinergic medications include diphenhydramine (Benadryl), many older antidepressants, bladder medications, some antipsychotics, and certain sleep aids. Acetylcholine is the primary neurotransmitter for memory and cognition, so blocking it chronically impairs cognitive function and has been linked to increased dementia risk in observational studies. For APOE4 carriers whose memory systems are already vulnerable, auditing anticholinergic burden and eliminating unnecessary medications is a high-leverage intervention often overlooked by physicians.

Definition

A plasma biomarker measuring phosphorylated tau at position 217, one of the most sensitive blood tests for detecting Alzheimer's pathology.

Plasma p-tau217 reflects brain tau pathology and correlates strongly with PET imaging and CSF tau measurements at a fraction of the cost and invasiveness. A result below 0.18 pg/mL is generally considered reassuring, while higher levels warrant further investigation. For APOE4 carriers, p-tau217 offers an objective tracking metric that doesn't require waiting for cognitive symptoms, making it a valuable addition to the bloodwork panel.

Both Parents Died of Alzheimer's. How One APOE4 Carrier Rebuilt His Life. | Phoenix Member Stories

Evidence-Based Content

Reviewed by Dr. Kevin Tran, PharmD · Based on peer-reviewed research · Updated

Updated recently

Key Takeaway

His p-tau came back at 0.09. But that's not even the best part of his story.

Categories

communityprotocolsnutrition
Dr. Kevin Tran
About the Author

Dr. Kevin Tran

PharmD

Dr. Kevin Tran is a Doctor of Pharmacy and APOE4/4 carrier dedicated to helping others with the APOE4 gene variant take proactive steps for their health. He founded The Phoenix Community to provide evidence-based resources and support for APOE4 carriers.

View all articles

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

Frequently Asked Questions

Can long-term Benadryl use cause dementia in APOE4 carriers?
Long-term use of diphenhydramine (Benadryl) and other anticholinergic medications has been associated with increased dementia risk in epidemiological studies. Diphenhydramine blocks acetylcholine, the neurotransmitter most directly involved in memory and cognition, and also suppresses deep sleep, which is when the glymphatic system clears amyloid-beta. For APOE4 carriers whose amyloid clearance is already impaired and whose stress/sleep cycles are genetically amplified, chronic anticholinergic use adds insult to injury. Phoenix member John Yoder took 50mg nightly for over 20 years for insomnia before learning the connection. He stopped immediately, and his subsequent p-tau217 test came back at 0.09, well below the 0.18 concern threshold. Safer alternatives for sleep include magnesium glycinate, glycine, and proper sleep hygiene.
Why do APOE4 carriers feel hangovers more than non-carriers?
APOE4 carriers tend to be hyper-reactive to alcohol. The body processes ethanol differently, and the downstream effects on blood-brain barrier permeability, glymphatic function, and inflammation are amplified compared to non-carriers. Phoenix member John Yoder spent years thinking his hangovers after 1-2 drinks were normal, asking friends how they were back at work already while he was wrecked. When he got his Oura ring, the data confirmed it: 1-2 beers and HRV would crash, readiness score tanked, and the next day's training was gone. This pattern is so common in Phoenix that members refer to it as the APOE4 alcohol ceiling. Standard drinking guidelines are calibrated to non-carriers and overestimate safe intake for carriers by a large margin.
What is a p-tau217 test and what does a normal result look like?
Plasma p-tau217 (phosphorylated tau at position 217) is a blood biomarker that tracks tau pathology, one of the two hallmark proteins in Alzheimer's disease. It's one of the most sensitive blood-based Alzheimer's biomarkers available today, available through providers like Care Access (which John Yoder found through Phoenix). A concerning threshold is approximately 0.18, while John's result came back at 0.09, reassuringly below concern despite 20 years of diphenhydramine use and family history. P-tau217 is particularly valuable for APOE4 carriers because it gives an objective measurement of brain pathology that does not depend on waiting for cognitive symptoms. Tracking p-tau over time lets you verify whether your interventions are actually protecting against amyloid and tau accumulation.
How quickly do APOE4 carriers feel the effects of starting a prevention protocol?
Within weeks, according to multiple Phoenix member stories including John Yoder's. He started his protocol (supplements, intermittent fasting, more protein, minimal alcohol) the same day he received his APOE 3/4 result and felt noticeably different within weeks: more energy, better sleep, sharper thinking. The conventional assumption is that Alzheimer's prevention is a distant 20-year bet with no feedback until then, but carriers who start optimizing report nearly immediate improvements in sleep, cognition, and energy. The short-term subjective improvements matter because they provide the feedback loop that keeps people on the protocol long enough to see the long-term pathology benefits.
Keep Reading

Related Protocols for You

More about community